Neurology · Dementia
The facts most likely to be tested
Press 1–5 to rate · ↑↓ to navigate
Mild Cognitive Impairment (MCI) is defined as a cognitive decline that is greater than expected for the patient's age and education level but does not interfere significantly with activities of daily living (ADLs).
The most common subtype is amnestic MCI, which primarily involves deficits in short-term memory and is a frequent precursor to Alzheimer disease.
Patients with MCI maintain functional independence, which is the critical clinical feature that distinguishes it from dementia.
The Mini-Mental State Examination (MMSE) or Montreal Cognitive Assessment (MoCA) are the preferred screening tools to document objective cognitive deficits.
Neuroimaging with MRI or CT is required to rule out reversible causes of cognitive decline such as normal pressure hydrocephalus, subdural hematoma, or brain tumors.
Laboratory evaluation must include TSH and Vitamin B12 levels to exclude metabolic or nutritional etiologies of cognitive impairment.
Management focuses on regular monitoring for progression to dementia and addressing modifiable risk factors such as hypertension, diabetes, and social isolation.
Vignette unlocked
A 74-year-old male is brought to the clinic by his daughter, who reports that he has become increasingly forgetful over the past year. The patient frequently forgets recent conversations and misplaces his keys, but he continues to manage his own finances, drive safely, and cook his own meals. On examination, he is alert and oriented, but he scores 24/30 on the Montreal Cognitive Assessment (MoCA) with specific deficits in delayed recall. His neurological exam is non-focal, and his TSH and Vitamin B12 levels are within normal limits.
What is the most likely diagnosis?
Mild Cognitive Impairment
The patient exhibits objective cognitive impairment on testing but maintains functional independence in his ADLs, which is the hallmark of MCI.
Full handout
High yield triage
Etiology / Epidemiology
Common in age >65; represents a transitional state between normal aging and dementia.
Clinical Manifestations
Subjective memory complaints with objective impairment on testing, but preserved activities of daily living (ADLs).
Diagnosis
Montreal Cognitive Assessment (MoCA) is the preferred screening tool; score <26 suggests impairment.
Treatment
No FDA-approved pharmacotherapy; focus on lifestyle modification and cognitive training.
Prognosis
High conversion rate to Alzheimer's disease, approximately 10-15% per year.
Full handout
Epidemiology & Etiology
Prevalence increases significantly with advanced age. Etiology is multifactorial, often involving neurodegenerative processes, vascular disease, or metabolic disturbances. It is defined as a clinical state where cognitive decline is greater than expected for age but does not meet criteria for dementia.
Pertinent Anatomy
Involves early atrophy of the hippocampus and entorhinal cortex. These structures are critical for memory consolidation, explaining the early amnestic presentation.
Pathophysiology
Often represents the prodromal phase of Alzheimer's disease, characterized by amyloid-beta plaques and tau protein neurofibrillary tangles. Vascular MCI may result from chronic small vessel disease or silent infarcts. The process involves a progressive loss of synaptic density in the neocortex.
Clinical Manifestations
Patients present with amnestic (memory loss) or non-amnestic (executive/language) deficits. Preserved functional independence is the hallmark differentiator from dementia. Red flags include rapid decline, focal neurologic deficits, or personality changes suggesting frontotemporal dementia.
Diagnosis
The Montreal Cognitive Assessment (MoCA) is superior to the MMSE for detecting early deficits. A score of <26 is the standard threshold for further evaluation. Diagnosis requires objective evidence of impairment in one or more cognitive domains via neuropsychological testing.
Treatment
There is no evidence-based pharmacotherapy; cholinesterase inhibitors (e.g., donepezil) are not indicated. Management focuses on physical exercise, Mediterranean diet, and management of vascular risk factors. Avoid anticholinergics as they worsen cognitive performance.
Prognosis
Patients are at high risk for progression to Alzheimer's disease. Annual cognitive reassessment is required to monitor for functional decline that would signal transition to dementia.
Differential Diagnosis
Alzheimer's disease: functional impairment present
Depression: pseudodementia with preserved effort on testing
Delirium: acute onset with fluctuating consciousness
Normal pressure hydrocephalus: wet, wobbly, and wacky triad
Hypothyroidism: reversible cognitive slowing